High Levels of Toxic Chemicals Found in Disposable Puff E-Cigarettes

Aug.03.2022
High Levels of Toxic Chemicals Found in Disposable Puff E-Cigarettes
One-time use Puff e-cigarettes contain high levels of unknown chemicals and synthetic coolants that are toxic to human cells.

A picture of a disposable puff electronic cigarette from Talbot Lab at the University of California, Riverside. Electronic cigarettes (EC) contain nicotine, solvents, and flavored chemicals, and are particularly popular among young people. In 2020, the US Food and Drug Administration (FDA) banned flavored EC pods based on cartridges, but this ban did not extend to "disposable" flavored EC products, such as Puff EC. Unfortunately, the chemical composition and toxicity of the liquid in Puff ECs is largely unknown.


Researchers from the University of California Riverside and Portland State University have examined 16 disposable Puff devices to determine their flavor chemicals, synthetic cooling agents, and nicotine concentrations. One of the synthetic cooling agents tested is WS-23 which provides a cooling sensation.


A team used gas chromatography and mass spectrometry to identify 126 flavor chemicals in Puff EC liquid and tested their toxicity on human bronchial epithelial cells. They reported in the journal Toxicology and Chemistry that the chemical content in single-use Puff EC was high and had cytotoxicity or toxicity to living cells.


Our data supports the need to regulate the flavoring chemicals and synthetic cooling agents in Puff EC to limit their potentially harmful effects on health," said Esther Omaiye, a former graduate student in the Environmental Toxicology Graduate Program and first author of the research paper. "The levels of nicotine, flavoring chemicals, and synthetic cooling agents in Puff EC are higher than those found in other consumer products, raising concerns about the safety of Puff products.


Omaiye, a postdoctoral researcher in the Prue Talbot laboratory, stated that one of the areas of regulatory concern related to e-cigarettes is the continuous development of novel chemicals in e-liquids.


For many years, we have been aware that EC design has been continuously evolving," said Talbot, the professor of cell biology leading the research team.


Recently, it has been discovered that chemicals used in e-cigarette liquids are changing. These changes are often made to make e-cigarette products more appealing to teenagers or to avoid regulation by the FDA, such as using synthetic nicotine instead of tobacco-derived nicotine to avoid FDA restrictions.


According to Talbot, the synthetic cooling agent WS-23, developed for use in shaving cream, is now included in EC liquids, but there is little information available about its inhalation toxicity.


Our work indicates that the concentration of WS-23 used in Puff ECs is sufficient to have negative long-term health effects," she said.


Other findings of the study include:


The EC in Puff contains a much higher concentration of synthetic cooling agents and flavor chemicals than JUUL EC.


Despite the unknown risks of inhaling, EC manufacturers are increasing the use and concentration of synthetic cooling agents, which is appealing to young users.


This article is compiled from third-party information and is intended only for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truth or accuracy of its contents. The compilation of this article is solely for industry exchange and research purposes.


Due to limitations in translation abilities, the compiled article may not fully express or accurately reflect the original text. Please refer to the original text for accuracy.


Regarding any domestic, Hong Kong, Macao, Taiwan, or international related statements and positions, 2FIRSTS fully aligns with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
British American Tobacco has appointed former Apple Senior Vice President, General Counsel and Secretary Bruce Sewell as an independent non-executive director, effective January 1, 2027. He will also join BAT's Audit and Nominations Committees. BAT Chair Luc Jobin highlighted Sewell's experience in technology, government and regulatory affairs, public-company governance and AI-company boards. Over the past 18 months, BAT has changed or announced changes to its CFO, general counsel, CMO and APMEA regional leadership, while the main board has also seen multiple changes. The appointment comes as BAT advances Horizon 2030 and its Fit2Win transformation while expanding New Categories and reshaping parts of its digital, technology and operating structure.
Business
Oct.29
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08